Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.53 |
| ▸ | ACHE | P22303 | 2/20 | 0.44 |
| ▸ | XDH | P47989 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | CDC25A | P30304 | 1/20 | 0.34 |
| ▸ | CDC25B | P30305 | 1/20 | 0.34 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.34 |
| ▸ | DHODH | Q02127 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23195480 | 0.92 | ALOX5 (0.51) | ALOX5KDM4EMEN1KMT2AAKR1B10 | |
| SCHEMBL316240 | 0.89 | ALOX5 (0.56) | ALOX5KDM4EMEN1KMT2AAKR1B10 | |
| SCHEMBL819795 | 0.87 | ALOX5 (0.71) | ALOX5KDM4EMEN1KMT2AAKR1B10 | |
| SCHEMBL12327984 | 0.87 | ALOX5 (0.71) | ALOX5KDM4EMEN1KMT2AAKR1B10 | |
| SCHEMBL26444131 | 0.86 | ALOX5 (0.44) | ALOX5KDM4EMEN1KMT2AAKR1B10 | |
| SCHEMBL30959751 | 0.83 | ALOX5 (0.63) | ALOX5KDM4EMEN1KMT2AAKR1B10 | |
| SCHEMBL31576807 | 0.83 | MEN1 (0.54) | ALOX5KDM4EMEN1KMT2AAKR1B10 | |
| SCHEMBL29405771 | 0.82 | ALOX5 (0.57) | ALOX5KDM4EMEN1KMT2AAKR1B10 | |
| SCHEMBL819253 | 0.81 | ALOX5 (0.78) | ALOX5KDM4EMEN1KMT2AAKR1B10 | |
| SCHEMBL13922241 | 0.81 | ALOX5 (0.52) | ALOX5KDM4EMEN1KMT2AAKR1B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 334 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026102053-A1 | FOAM ENHANCING PHOSPHOLIPID EMULSION SYSTEMS | ABSTRAX TECH INC. (US) | 2026-05-15 | — | — | WO | claimed |
| US-20260123653-A1 | Foam Enhancing Phospholipid Emulsion Systems | ABSTRAX TECH INC (US) | 2026-05-07 | — | — | US | claimed |
| US-20260125625-A1 | HOPS ACIDS STABILIZED EMULSIONS | ABSTRAX TECH INC (US) | 2026-05-07 | — | — | US | claimed |
| EP-4312981-B1 | EDIBLE ORAL COMPOSITIONS COMPRISING HOPS | PROCTER & GAMBLE (US) | 2025-11-05 | — | — | EP | claimed |
| EP-4640205-A2 | ORAL CARE COMPOSITIONS COMPRISING HOPS BETA ACID AND FLUORIDE | The Procter & Gamble Company (US) | 2025-10-29 | — | — | EP | claimed |
| EP-4623074-A1 | RECOMBINANT POLYPEPTIDES WITH PRENYLTRANSFERASE ACTIVITY FOR BIOSYNTHESIS OF CANNABINOIDS AND HOP COMPOUNDS | Epimeron USA, Inc. (US) | 2025-10-01 | — | — | EP | claimed |
| US-20250295565-A1 | Oral Care Compositions Comprising Hops Beta Acids And Fluoride Ions | PROCTER & GAMBLE (US) | 2025-09-25 | — | — | US | claimed |
| US-20250270598-A1 | RECOMBINANT POLYPEPTIDES WITH PRENYLTRANSFERASE ACTIVITY FOR BIOSYNTHESIS OF CANNABINOIDS AND HOP COMPOUNDS | EPIMERON USA, INC. (US) | 2025-08-28 | — | — | US | claimed |
| EP-4037765-B1 | ORAL CARE COMPOSITIONS COMPRISING HOPS BETA ACID AND AMINO ACID | PROCTER & GAMBLE (US) | 2025-08-20 | — | — | EP | claimed |
| US-12350355-B2 | Oral care compositions comprising hops beta acids and fluoride ions | THE PROCTER & GAMBLE COMPANY (US) | 2025-07-08 | — | — | US | claimed |
| EP-4037781-A1 | FLUORIDE-FREE ANTICAVITY ORAL CARE COMPOSITIONS | The Procter & Gamble Company (US) | 2022-08-10 | — | — | EP | claimed |
| CN-114466642-A | Oral care compositions comprising hops beta acids and fluoride | 宝洁公司 | 2022-05-10 | — | — | CN | claimed |
| CN-114449996-A | Oral care compositions comprising hops beta acids and metal ions | 宝洁公司 | 2022-05-06 | — | — | CN | claimed |
| US-20220096363-A1 | Oral Care Composition Comprising Hops And Flavor | THE PROCTER & GAMBLE COMPANY | 2022-03-31 | — | — | US | claimed |
| WO-2022067141-A1 | AQUEOUS COMPOSITIONS COMPRISING HOPS-METAL COMPLEX | THE PROCTER & GAMBLE COMPANY (US) | 2022-03-31 | — | — | WO | claimed |
| US-20220096362-A1 | Aqueous Compositions Comprising Hops-Metal Complex | THE PROCTER & GAMBLE COMPANY | 2022-03-31 | — | — | US | claimed |
| US-20110275721-A1 | METHOD FOR THE PURIFICATION OF SUBSTITUTED CYCLOPENT-2-EN-1-ONE CONGENERS AND SUBSTITUTED 1,3-CYCLOPENTADIONE CONGENERS FROM A COMPLEX MIXTURE USING COUNTERCURRENT SEPARATION | METAPROTEOMICS, LLC (US) | 2011-11-10 | — | — | US | claimed |
| US-20110257074-A1 | METHOD FOR THE PURIFICATION OF SUBSTITUTED CYCLOPENT-2-EN-1-ONE CONGENERS AND SUBSTITUTED 1,3-CYCLOPENTADIONE CONGENERS FROM A COMPLEX MIXTURE USING COUNTERCURRENT SEPARATION | METAPROTEOMICS, LLC (US) | 2011-10-20 | — | — | US | claimed |
| EP-2364083-A1 | A METHOD FOR THE PURIFICATION OF SUBSTITUTED CYCLOPENT-2-EN-1-ONE CONGENERS AND SUBSTITUTED 1,3-CYCLOPENTADIONE CONGENERS FROM A COMPLEX MIXTURE USING COUNTERCURRENT SEPARATION | Metaproteomics, LLC (US) | 2011-09-14 | — | — | EP | claimed |
| WO-2010068731-A1 | A METHOD FOR THE PURIFICATION OF SUBSTITUTED CYCLOPENT-2-EN-1-ONE CONGENERS AND SUBSTITUTED 1,3-CYCLOPENTADIONE CONGENERS FROM A COMPLEX MIXTURE USING COUNTERCURRENT SEPARATION | METAPROTEOMICS, LLC (US) | 2010-06-17 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250295565-A1 | Oral Care Compositions Comprising Hops Beta Acids And Fluoride Ions | HAX1, AP3S1, AFF1 | ALOX5 4473/4885KDM4E 4723/4885MEN1 2268/4885 |
| US-20220096362-A1 | Aqueous Compositions Comprising Hops-Metal Complex | TPR, AP2S1, AP1S1 | ALOX5 2840/4885KDM4E 4876/4885MEN1 152/4885 |
| US-20260125625-A1 | HOPS ACIDS STABILIZED EMULSIONS | HAO2, NIPSNAP1, AP2S1 | ALOX5 1575/4885KDM4E 4861/4885MEN1 3371/4885 |
| US-20220096363-A1 | Oral Care Composition Comprising Hops And Flavor | TAS1R1, TAS1R3, FGF1 | ALOX5 3164/4885KDM4E 1269/4885MEN1 1204/4885 |
| US-20110275721-A1 | METHOD FOR THE PURIFICATION OF SUBSTITUTED CYCLOPENT-2-EN-1-ONE CONGENERS AND SUBSTITUTED 1,3-CYCLOPENTADIONE CONGENERS FROM A COMPLEX MIXTURE USING COUNTERCURRENT SEPARATION | CYCS, CYP1B1, PDE1C | ALOX5 1912/4885KDM4E 3288/4885MEN1 4344/4885 |
| US-20260123653-A1 | Foam Enhancing Phospholipid Emulsion Systems | PHOSPHO1, PLTP, PLIN3 | ALOX5 165/4885KDM4E 1930/4885MEN1 1095/4885 |
| US-20110257074-A1 | METHOD FOR THE PURIFICATION OF SUBSTITUTED CYCLOPENT-2-EN-1-ONE CONGENERS AND SUBSTITUTED 1,3-CYCLOPENTADIONE CONGENERS FROM A COMPLEX MIXTURE USING COUNTERCURRENT SEPARATION | CYCS, CYP1B1, PDE1C | ALOX5 1912/4885KDM4E 3288/4885MEN1 4344/4885 |
| US-12350355-B2 | Oral care compositions comprising hops beta acids and fluoride ions | HAX1, AP3S1, AFF1 | ALOX5 4473/4885KDM4E 4723/4885MEN1 2268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.